Supplementary Table 1.TagSNPs and candidate polymorphisms in PTGS1 and PTGS2.
Gene / DALS / CCFR / SNP name / Location / Chr Pos (build 37.3) / MAF DALS (%) / MAFCCFR (%) / CommentPTGS1 / rs1330344 / -1676 T>C / 5' (outside UTR) / 125131688 / 21.1 / failed QC
rs10306225 / -1532 A>T / 5' (outside UTR) / 125131832 / 0.8
rs10306110a / -1053 A>G / 5' (outside UTR) / 125132311 / 7.1
rs1236913 / rs1236913 / R8W (22 C>T) / exon 2 / 125133479 / 6.8 / 6.6 / Candidate
none / none / L15-L16del / exon 2 / 125133501 / 0.7 / 0.6 / Candidate
rs3842787a / rs3842787 / P17L (50 C>T) / exon 2 / 125133507 / 7.2 / 6.9 / Candidate
rs3119773 / 1890 G>A / intron 2 / 125135254 / 14.1
rs10306122 / 2125 T>C / intron 2 / 125135489 / 6.3
rs10306135 / rs10306135 / 4331 A>T / intron 2 / 125137695 / 14.5 / 14.4
rs5787 / R108Q (323 G>A) / exon 4 / 125140823 / 0.0 / Candidate/
monomorphic
rs10306140 / R149L (446 G>T) / exon 5 / 125141147 / 0.1 / Candidate/
monomorphic
rs10306141b / 8343 T>C / intron 5 / 125141707 / 13.0
rs5789 / rs5789 / L237M (709 C>A) / exon 7 / 125143973 / 2.7 / 3.0 / Candidate
rs1238420 / 10781 G>A / intron 7 / 125144145 / 6.4
rs3119774 / 13108 A>G / intron 8 / 125146472 / ND / failed QC
rs9299281b / 14507 A>G / intron 8 / 125147871 / 14.0
rs6478565c / rs6478565 / 15268 A>G / intron 8 / 125148632 / 17.4 / 16.8
rs10306164c / 16569 T>G / intron 9 / 125150003 / 16.7
rs10306194 / 23835 C>A / 3' UTR / 125157198 / 15.3
Gene / DALS / CCFR / SNP name / Location / Chr Pos (build 37.3) / MAF DALS (%) / MAFCCFR (%) / Comment
PTGS2 / rs4648250 / rs4648250 / -1740 A>G / 5' (outside UTR) / 186651296 / 0.8 / 0.5
rs689466 / rs689466 / -1195 A>G / 5' (outside UTR) / 186650751 / 19.0 / 19.1
rs20417d / rs20417 / -765 G>C / 5' (outside UTR) / 186650321 / 16.1 / 16.3 / Candidate
rs5270 / -163 C>G / 5' (outside UTR) / 186649719 / 0.1 / Candidate/
monomorphic
rs20424 / rs20424 / -62 C>G / 5' (outside UTR) / 186649618 / 1.6 / 1.6
rs2745557 / rs2745557 / 201 G>A / intron 1 / 186649221 / 16.8 / 18.1
rs4648261 / rs4648261 / 418 G>A / intron 1 / 186649004 / 3.0 / 3.4
rs5277 / V102V (306 C>G) / exon 3 / 186648197 / 15.6
rs4648268 / rs4648268 / 2284 G>A / intron 4 / 186647138 / 10.2 / 10.4
rs20432d / 3099 A>C / intron 5 / 186646323 / 15.8
rs2066826d / 3495 G>A / intron 6 / 186645927 / 13.5
rs4648276d / 3934 T>C / intron 7 / 186645488 / 13.5
rs5275 / rs5275 / 6364 T>C / 3' UTR / 186643058 / 35.1 / 34.8
rs2206593 / 6993 C>T / 3' UTR / 186642429 / 5.9
rs689469 / 8225 G>A / 3' UTR / 186641197 / 2.2
rs4648308d / 8805 G>A / 3' (outside UTR) / 186640617 / 15.6
rs4648310 / 8897 A>G / 3' (outside UTR) / 186640525 / 3.1
a, b, c, d These groups of SNPs are in high linkage disequilibrium (r2>0.9); the italicized SNP in each group was not included in the main analysis.
Supplementary Figure 1.(A)PTGS1and (B) PTGS2pairwise linkage disequilibrium (r2) among Caucasian DALS colon cancer controls. LD structure was similar in theDALS rectal cancer study.
A.
B.
Supplementary Table 2.Association between PTGS1 and PTGS2polymorphisms and risk of colon and rectal cancer in the DALS study.
Colon Cancer / Rectal CancerControls / Cases / Controls / Cases
SNP / Genotype / N / % / N / % / OR / 95% CI / LRTpb / minPc / N / % / N / % / OR / 95% CI / LRTpb / minPc
PTGS1
rs10306225 / A/A / * / 1753 / 98.6 / 1408 / 98.9 / ref / - / - / 0.46 / * / 758 / 97.8 / 572 / 98.1 / ref / - / - / 0.69
A/T / 25 / 1.4 / 15 / 1.1 / 0.78 / 0.41 / 1.50 / 17 / 2.2 / 11 / 1.9 / 0.86 / 0.40 / 1.85
rs1236913 / C/C / * / 1608 / 87.6 / 1273 / 86.6 / ref / - / - / 0.35 / * / 668 / 87.3 / 491 / 85.7 / ref / - / - / 0.34
C/T / 211 / 11.5 / 188 / 12.8 / 1.10 / 0.90 / 1.35 / 93 / 12.2 / 79 / 13.8 / 1.17 / 0.85 / 1.60
T/T / 16 / 0.9 / 9 / 0.6 / 4 / 0.5 / 3 / 0.5
L15L16del / No del / * / 1770 / 98.9 / 1411 / 98.7 / ref / - / - / 0.63 / * / 752 / 98.3 / 559 / 97.9 / ref / - / - / 0.55
Deletion / 19 / 1.1 / 18 / 1.3 / 1.17 / 0.61 / 2.25 / 13 / 1.7 / 12 / 2.1 / 1.28 / 0.58 / 2.83
rs3842787 / C/C / 1546 / 86.6 / 1231 / 86.2 / ref / - / - / 0.94 / * / 668 / 87.2 / 490 / 85.4 / ref / - / - / 0.35
C/T / 228 / 12.8 / 187 / 13.1 / 1.04 / 0.84 / 1.28 / 93 / 12.1 / 79 / 13.8 / 1.16 / 0.85 / 1.59
T/T / 12 / 0.7 / 10 / 0.7 / 1.01 / 0.44 / 2.36 / 5 / 0.7 / 5 / 0.9
rs3119773 / G/G / 1321 / 74.8 / 1023 / 73.3 / ref / - / - / 0.53 / 575 / 75.1 / 419 / 72.2 / ref / - / - / 0.34
G/A / 406 / 23.0 / 334 / 23.9 / 1.07 / 0.90 / 1.26 / 179 / 23.4 / 147 / 25.3 / 1.13 / 0.88 / 1.46
A/A / 40 / 2.3 / 38 / 2.7 / 1.23 / 0.78 / 1.93 / 12 / 1.6 / 14 / 2.4 / 1.59 / 0.73 / 3.48
rs10306122 / A/A / * / 1571 / 88.4 / 1239 / 87.3 / ref / - / - / 0.42 / * / 675 / 87.2 / 505 / 86.8 / ref / - / - / 0.80
A/G / 201 / 11.3 / 177 / 12.5 / 1.09 / 0.88 / 1.35 / 98 / 12.7 / 74 / 12.7 / 1.04 / 0.76 / 1.44
G/G / 5 / 0.3 / 4 / 0.3 / 1 / 0.1 / 3 / 0.5
rs10306135 / T/T / 1295 / 73.5 / 1009 / 71.7 / ref / - / - / 0.55 / * / 577 / 74.5 / 432 / 74.4 / ref / - / - / 0.91
T/A / 428 / 24.3 / 367 / 26.1 / 1.09 / 0.93 / 1.29 / 176 / 22.7 / 140 / 24.1 / 1.01 / 0.79 / 1.30
A/A / 40 / 2.3 / 32 / 2.3 / 1.02 / 0.64 / 1.64 / 21 / 2.7 / 9 / 1.5
rs5789 / C/C / * / 1738 / 94.7 / 1394 / 94.8 / ref / - / - / 0.82 / * / 732 / 94.6 / 551 / 94.5 / ref / - / - / 0.97
C/A / 95 / 5.2 / 73 / 5.0 / 0.96 / 0.71 / 1.32 / 40 / 5.2 / 32 / 5.5 / 1.01 / 0.63 / 1.62
A/A / 2 / 0.1 / 3 / 0.2 / 2 / 0.3 / 0 / 0.0
rs1238420 / G/G / * / 1549 / 87.9 / 1229 / 87.5 / ref / - / - / 0.74 / * / 682 / 88.0 / 502 / 86.3 / ref / - / - / 0.36
G/A / 208 / 11.8 / 168 / 12.0 / 1.04 / 0.84 / 1.29 / 92 / 11.9 / 76 / 13.1 / 1.16 / 0.84 / 1.60
A/A / 6 / 0.3 / 7 / 0.5 / 1 / 0.1 / 4 / 0.7
rs9299281 / A/A / 1318 / 74.3 / 1062 / 74.7 / ref / - / - / 0.93 / * / 569 / 73.8 / 427 / 73.4 / ref / - / - / 0.82
A/G / 413 / 23.3 / 327 / 23.0 / 0.98 / 0.83 / 1.15 / 183 / 23.7 / 149 / 25.6 / 1.03 / 0.81 / 1.31
G/G / 43 / 2.4 / 32 / 2.3 / 0.93 / 0.59 / 1.49 / 19 / 2.5 / 6 / 1.0
rs6478565 / A/A / 1197 / 67.9 / 972 / 68.8 / ref / - / - / 0.77 / 536 / 69.2 / 397 / 68.2 / ref / - / - / 0.18
A/G / 507 / 28.8 / 398 / 28.2 / 0.96 / 0.82 / 1.12 / 209 / 27.0 / 172 / 29.6 / 1.11 / 0.88 / 1.42
G/G / 58 / 3.3 / 42 / 3.0 / 0.89 / 0.59 / 1.34 / 30 / 3.9 / 13 / 2.2 / 0.60 / 0.31 / 1.17
rs10306194 / C/C / 1267 / 71.5 / 1047 / 74.0 / ref / - / - / 0.27 / 0.97 / 536 / 69.2 / 416 / 71.5 / ref / - / - / 0.61
C/A / 462 / 26.1 / 340 / 24.0 / 0.90 / 0.77 / 1.06 / 216 / 27.9 / 148 / 25.4 / 0.88 / 0.69 / 1.13
A/A / 42 / 2.4 / 27 / 1.9 / 0.76 / 0.46 / 1.24 / 23 / 3.0 / 18 / 3.1 / 1.02 / 0.54 / 1.92
PTGS2
rs4648250 / A/A / * / 1715 / 97.9 / 1376 / 98.6 / ref / - / - / 0.09 / 0.68 / * / 748 / 575 / ref / - / -
A/G / 37 / 2.1 / 19 / 1.4 / 0.63 / 0.36 / 1.10 / 11 / 2
rs689466 / A/A / 1198 / 67.5 / 910 / 64.0 / ref / - / - / 0.15 / 509 / 65.7 / 376 / 64.7 / ref / - / - / 0.87
A/G / 509 / 28.7 / 455 / 32.0 / 1.16 / 1.00 / 1.36 / 237 / 30.6 / 185 / 31.8 / 1.06 / 0.83 / 1.33
G/G / 67 / 3.8 / 57 / 4.0 / 1.10 / 0.76 / 1.58 / 29 / 3.7 / 20 / 3.4 / 0.94 / 0.52 / 1.68
rs20417 / G/G / 1232 / 69.6 / 979 / 68.9 / ref / - / - / 0.95 / 553 / 71.4 / 433 / 74.3 / ref / - / - / 0.05 / 0.40
G/C / 495 / 28.0 / 404 / 28.5 / 1.02 / 0.87 / 1.20 / 211 / 27.2 / 134 / 23.0 / 0.81 / 0.63 / 1.04
C/C / 44 / 2.5 / 37 / 2.6 / 1.04 / 0.67 / 1.63 / 11 / 1.4 / 16 / 2.7 / 1.95 / 0.89 / 4.26
rs20424 / C/C / * / 1726 / 97.2 / 1379 / 97.2 / ref / - / - / 0.91 / * / 748 / 96.6 / 556 / 95.4 / ref / - / - / 0.22
C/G / 48 / 2.7 / 40 / 2.8 / 1.02 / 0.67 / 1.57 / 25 / 3.2 / 27 / 4.6 / 1.41 / 0.81 / 2.45
G/G / 1 / 0.1 / 0 / 0.0 / 1 / 0.1 / 0 / 0.0
rs2745557 / G/G / 1233 / 69.6 / 981 / 69.5 / ref / - / - / 0.98 / 534 / 68.9 / 392 / 67.5 / ref / - / - / 0.45
G/A / 492 / 27.8 / 394 / 27.9 / 1.01 / 0.86 / 1.18 / 214 / 27.6 / 174 / 29.9 / 1.10 / 0.87 / 1.40
A/A / 47 / 2.7 / 36 / 2.6 / 0.96 / 0.62 / 1.50 / 27 / 3.5 / 15 / 2.6 / 0.75 / 0.39 / 1.42
rs4648261 / G/G / * / 1664 / 94.0 / 1332 / 93.9 / ref / - / - / 0.90 / * / 732 / 94.6 / 546 / 94.1 / ref / - / - / 0.70
G/A / 106 / 6.0 / 85 / 6.0 / 1.02 / 0.76 / 1.37 / 42 / 5.4 / 33 / 5.7 / 1.10 / 0.69 / 1.75
A/A / 1 / 0.1 / 1 / 0.1 / 0 / 0.0 / 1 / 0.2
rs5277 / C/C / 1254 / 71.3 / 1006 / 71.5 / ref / - / - / 0.92 / 538 / 69.5 / 413 / 70.8 / ref / - / - / 0.49
C/G / 475 / 27.0 / 375 / 26.7 / 0.99 / 0.84 / 1.16 / 207 / 26.7 / 155 / 26.6 / 0.98 / 0.77 / 1.25
G/G / 29 / 1.6 / 26 / 1.8 / 1.10 / 0.64 / 1.88 / 29 / 3.7 / 15 / 2.6 / 0.68 / 0.36 / 1.29
rs4648268 / G/G / 1443 / 81.2 / 1148 / 80.7 / ref / - / - / 0.14 / * / 626 / 80.8 / 462 / 79.2 / ref / - / - / 0.47
G/A / 322 / 18.1 / 253 / 17.8 / 0.99 / 0.82 / 1.19 / 141 / 18.2 / 112 / 19.2 / 1.10 / 0.84 / 1.44
A/A / 13 / 0.7 / 21 / 1.5 / 1.98 / 0.99 / 3.98 / 8 / 1.0 / 9 / 1.5
rs5275 / A/A / 725 / 40.8 / 599 / 42.2 / ref / - / - / 0.20 / 342 / 44.2 / 252 / 43.2 / ref / - / - / 0.91
A/G / 805 / 45.4 / 655 / 46.1 / 0.99 / 0.86 / 1.16 / 344 / 44.4 / 265 / 45.5 / 1.05 / 0.84 / 1.32
G/G / 245 / 13.8 / 166 / 11.7 / 0.82 / 0.66 / 1.03 / 88 / 11.4 / 66 / 11.3 / 1.02 / 0.71 / 1.47
rs2206593 / G/G / * / 1574 / 88.5 / 1262 / 88.7 / ref / - / - / 0.90 / * / 685 / 88.7 / 518 / 88.9 / ref / - / - / 0.90
G/A / 195 / 11.0 / 154 / 10.8 / 0.99 / 0.79 / 1.23 / 85 / 11.0 / 65 / 11.1 / 0.98 / 0.69 / 1.38
A/A / 10 / 0.6 / 6 / 0.4 / 2 / 0.3 / 0 / 0.0
rs689469 / G/G / * / 1694 / 95.4 / 1364 / 95.9 / ref / - / - / 0.45 / * / 742 / 95.7 / 564 / 96.7 / ref / - / - / 0.32
G/A / 80 / 4.5 / 57 / 4.0 / 0.88 / 0.62 / 1.24 / 32 / 4.1 / 19 / 3.3 / 0.75 / 0.42 / 1.33
A/A / 2 / 0.1 / 2 / 0.1 / 1 / 0.1 / 0 / 0.0
rs4648310 / A/A / * / 1667 / 93.9 / 1345 / 94.5 / ref / - / - / 0.48 / * / 718 / 92.6 / 553 / 94.9 / ref / - / - / 0.08
A/G / 104 / 5.9 / 77 / 5.4 / 0.90 / 0.66 / 1.21 / 57 / 7.4 / 30 / 5.1 / 0.67 / 0.43 / 1.06
a Adjusted for age, sex, and center.
b Global p-value from a likelihood ratio test prior to correction for multiple comparisons.
cminP permutation test based on 10,000 replications, p-values not presented were non-significant (minP > 0.05)
* Dominant model.
The dominant model was used when<10 cases or controls had the homozygous variant genotype,modeling was not run if <5 cases or controls were heterozygotes.
- 1 -
Supplementary Table 3.Interactions between selected PTGS2SNPs, aspirin use, and risk of colon and rectal cancer.a
Colon Cancer / Rectal CancerAspirin Use: / Never/Former / Current / Never/Former / Current
Control / Case / OR / 95% CI / p / Control / Case / OR / 95% CI / p / int pe / Control / Case / OR / 95% CI / p / Control / Case / OR / 95% CI / p / int pe
PTGS2
rs689466 (-1195 A>G)
DALSb / A/A / 840 / 707 / ref / - / - / - / 354 / 198 / 0.63 / 0.51 / 0.78 / 0.00 / 0.28 / 340 / 282 / ref / - / - / - / 166 / 92 / 0.65 / 0.48 / 0.89 / 0.01 / 0.01
A/G / 341 / 361 / 1.27 / 1.06 / 1.52 / 0.01 / 166 / 92 / 0.62 / 0.47 / 0.82 / 0.00 / 200 / 142 / 0.88 / 0.67 / 1.16 / 0.37 / 65 / 61 / 1.11 / 0.75 / 1.64 / 0.62
G/G / 51 / 45 / 0.99 / 0.65 / 1.51 / 0.96 / 16 / 11 / 0.83 / 0.38 / 1.82 / 0.64 / * / * / * / *
CCFRc / A/A / 779 / 518 / ref / - / - / - / 164 / 96 / 0.78 / 0.55 / 1.11 / 0.17 / 0.40 / 475 / 294 / ref / - / - / - / 75 / 42 / 0.73 / 0.41 / 1.30 / 0.29 / 0.21
A/G+G/G / 456 / 259 / 0.83 / 0.62 / 1.12 / 0.23 / 94 / 58 / 0.83 / 0.52 / 1.31 / 0.41 / 230 / 130 / 0.96 / 0.65 / 1.43 / 0.86 / 33 / 28 / 1.25 / 0.60 / 2.61 / 0.55
rs2745557 (201 G>A)
DALSb / G/G / 862 / 765 / ref / - / - / - / 368 / 210 / 0.62 / 0.50 / 0.75 / 0.00 / 0.52 / 391 / 286 / ref / - / - / - / 140 / 104 / 0.97 / 0.72 / 1.32 / 0.87 / 0.03
G/A+A/A / 370 / 338 / 1.07 / 0.89 / 1.28 / 0.48 / 166 / 90 / 0.58 / 0.44 / 0.77 / 0.00 / 149 / 139 / 1.26 / 0.95 / 1.66 / 0.11 / 91 / 48 / 0.70 / 0.47 / 1.03 / 0.07
CCFRc / G/G / 852 / 519 / ref / - / - / - / 179 / 122 / 1.10 / 0.80 / 1.50 / 0.56 / 0.001f / 473 / 268 / ref / - / - / - / 75 / 51 / 1.10 / 0.65 / 1.86 / 0.72 / 0.33
G/A+A/A / 393 / 274 / 1.26 / 0.94 / 1.70 / 0.13 / 85 / 34 / 0.51 / 0.29 / 0.89 / 0.02 / 243 / 152 / 1.28 / 0.84 / 1.94 / 0.25 / 34 / 20 / 0.91 / 0.41 / 2.04 / 0.82
rs4648261 (418 G>A)
DALSb / G/G / 1162 / 1058 / ref / - / - / - / 497 / 266 / 0.56 / 0.47 / 0.66 / 0.00 / 0.01 / 516 / 400 / ref / - / - / - / 212 / 142 / 0.84 / 0.65 / 1.09 / 0.19 / 0.37
G/A+A/A / 71 / 52 / 0.82 / 0.56 / 1.19 / 0.30 / 35 / 34 / 1.06 / 0.65 / 1.73 / 0.81 / 23 / 23 / 1.31 / 0.72 / 2.38 / 0.38 / 19 / 11 / 0.70 / 0.33 / 1.51 / 0.36
CCFRc / G/G / 1168 / 752 / ref / - / - / - / 242 / 142 / 0.81 / 0.61 / 1.07 / 0.14 / 0.11 / 655 / 413 / ref / - / - / - / 102 / 64 / 0.86 / 0.55 / 1.36 / 0.53 / 0.19
G/A+A/A / 79 / 41 / 0.38 / 0.20 / 0.75 / 0.01 / 22 / 14 / 0.70 / 0.29 / 1.71 / 0.43 / 61 / 18 / 0.48 / 0.20 / 1.17 / 0.11 / 7 / 7 / 1.17 / 0.28 / 4.94 / 0.83
* Dominant model.
a Only SNPs genotyped in both DALS and CCFR with an interaction p-value <0.05 are shown. The dominant model was used when <10 cases or controls had the homozygous variant genotype, modeling was not run if <5 cases or controls were heterozygotes.
b Adjusted for age, sex, center, BMI, smoking, physical activity, calcium, calories, and dietary fiber.
c Adjusted for age, sex, BMI, smoking and physical activity.
d Current aspirin use is defined as current, regular use three times per week for at least one month in the DALS study and as current, regular use of at least two pills per week for at least one month for the CCFR study.
e Interaction p-value from a likelihood ratio test prior to correction for multiple comparisons. No SNPs remained significant in the DALS studies after correcting for multiple comparisons using minP permutation tests (minP ≤ 0.05).
f This interaction remained significant after correcting for multiple comparisons; minP < 0.01.
Supplementary Table 4.Interactions between selected PTGS2SNPs, NSAID use, and risk of colon and rectal cancer.a
Colon Cancer / Rectal CancerNSAID Use / Never/Former / Current / Never/Former / Current
Controls / Cases / OR / 95% CI / Controls / Cases / OR / 95% CI / pe / minPf / Controls / Cases / OR / 95% CI / Controls / Cases / OR / 95% CI / pe / minPf
PTGS2
rs689466 (-1195 A>G)
DALSb / A/A / 704 / 600 / ref / - / - / 488 / 300 / 0.67 / 0.56 / 0.81 / 0.37 / - / 259 / 235 / ref / - / - / 248 / 139 / 0.60 / 0.45 / 0.79 / 0.15 / -
A/G / 272 / 302 / 1.31 / 1.07 / 1.60 / 234 / 151 / 0.71 / 0.56 / 0.90 / 153 / 123 / 0.92 / 0.68 / 1.24 / 111 / 81 / 0.78 / 0.55 / 1.10
G/G / 43 / 40 / 1.01 / 0.64 / 1.60 / 24 / 16 / 0.76 / 0.40 / 1.46 / * / * / * / *
CCFRc / A/A / 722 / 486 / ref / - / - / 226 / 130 / 0.73 / 0.54 / 1.00 / 0.03 / - / 440 / 281 / ref / - / - / 114 / 57 / 0.67 / 0.42 / 1.06 / 0.20 / -
A/G / 367 / 213 / 0.81 / 0.60 / 1.10 / 126 / 73 / 0.78 / 0.51 / 1.21 / 208 / 124 / 0.94 / 0.63 / 1.39 / 58 / 34 / 1.02 / 0.55 / 1.92
G/G / 50 / 22 / 0.61 / 0.30 / 1.20 / 12 / 11 / 2.09 / 0.74 / 5.90 / * / * / * / *
rs20417 (-765 G>C)
DALSb / G/G / 701 / 647 / ref / - / - / 524 / 320 / 0.61 / 0.51 / 0.74 / 0.81 / - / 298 / 264 / ref / - / - / 253 / 167 / 0.71 / 0.55 / 0.93 / 0.44 / -
G/C / 294 / 269 / 0.98 / 0.80 / 1.20 / 199 / 134 / 0.67 / 0.52 / 0.86 / 114 / 95 / 0.94 / 0.68 / 1.31 / 106 / 54 / 0.55 / 0.38 / 0.80
C/C / 24 / 25 / 1.08 / 0.60 / 1.93 / 20 / 12 / 0.66 / 0.32 / 1.37 / * / * / * / *
CCFRc / G/G / 789 / 501 / ref / - / - / 260 / 143 / 0.82 / 0.61 / 1.10 / 0.39 / - / 455 / 252 / ref / - / - / 115 / 62 / 1.05 / 0.67 / 1.64 / 0.03 / -
G/C+CC / 331 / 211 / 1.03 / 0.76 / 1.41 / 98 / 69 / 1.06 / 0.68 / 1.66 / 187 / 138 / 1.56 / 1.03 / 2.34 / 54 / 27 / 0.66 / 0.32 / 1.35
rs2745557 (201 G>A)
DALSb / G/G / 715 / 651 / ref / - / - / 514 / 323 / 0.66 / 0.55 / 0.78 / 0.80 / - / 293 / 244 / ref / - / - / 239 / 146 / 0.70 / 0.53 / 0.92 / 0.57 / -
G/A / 277 / 260 / 1.08 / 0.88 / 1.33 / 210 / 128 / 0.63 / 0.49 / 0.82 / 119 / 115 / 1.14 / 0.84 / 1.56 / 120 / 73 / 0.69 / 0.49 / 0.98
A/A / 27 / 24 / 1.01 / 0.57 / 1.79 / 20 / 12 / 0.59 / 0.28 / 1.24 / * / * / * / *
CCFRc / G/G / 789 / 481 / ref / - / - / 249 / 164 / 1.13 / 0.85 / 1.49 / <0.01 / <0.01 / 436 / 257 / ref / - / - / 116 / 64 / 0.88 / 0.57 / 1.37 / 0.55 / -
G/A+A/A / 358 / 255 / 1.36 / 1.00 / 1.84 / 123 / 54 / 0.59 / 0.38 / 0.93 / 223 / 154 / 1.22 / 0.80 / 1.84 / 57 / 28 / 0.86 / 0.45 / 1.65
* Dominant model.
a Only SNPs with an interaction p ≤ 0.05 in the CCFR study are shown. The dominant model was used when <10 cases or controls had the homozygous variant genotype, modeling was not run if <5 cases or controls were heterozygotes.
b Adjusted for age, sex, center, BMI, smoking, physical activity, calcium, calories, and dietary fiber.
c Adjusted for age, sex, BMI, smoking and physical activity.
d Current NSAID use is defined as current, and regular use 3x/week for 1 month in the DALS studies and current, regular use of at least 2 pills per week for at least one month in the CCFR study.
e Interaction p-value from a likelihood ratio test prior to correction for multiple comparisons.
fminP permutation test based on 10,000 replications, p-values not presented were non-significant (minP > 0.05).
- 1 -